Physician Resources: Liver Transplantation and HCC
Dr. Amit Tevar discusses Hepatocellular Carcinoma and how liver transplantation treatment options are centered around treatment of the tumor and the underlying disease.
Upon completion of this activity, participants should be able to:
- Identify which tumor markers can accurately predict poor outcomes following liver transplant with HCC
- Recognize which tumor size or number of lesions are eligible for MELD exception through UNOS and increase effective listing of patients
- Describe how long HCC patients with T2 exception will need to wait before receiving their first exception upgrade and improve patient outcomes
Dr. Amit D. Tevar has financial interests with the following entity or entities producing health care goods or services as indicated below:
Dr. Tevar is on the Advisory Board for CSL Behring
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (.075) continuing education units (CEU) which are equivalent to .75 contact hour.
- 0.75 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 0.75 Attendance